News
Gilead's top late-stage drug selonsertib, for patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), has failed a phase 3 trial. The drug, an apoptosis signal-regulating ...
The road to the development of treatments for non-alcoholic steatohepatitis (NASH) is littered with failed projects, but US biotech Madrigal Pharma thinks it now has enough evidence for its drug ...
Tales of the Princess Patricia's Canadian Light Infantry and the Ric-A-Dam-Doo For 100 years, the Princess Patricia's Canadian Light Infantry has been one of the most storied and well-known ...
Products Market Alerts MyCollection Price Database Become a Partner Gallery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results